EUCTR2005-003293-25-IT进行中（未招募）不适用
A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF MELPHALAN, PREDNISONE, THALIDOMIDE AND DEFIBROTIDE IN ADVANCED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO0 个研究点目标入组 38 人开始时间: 2005年10月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A PHASE II, MULTI-CENTRE, OPEN LABEL STUDY OF MELPHALAN, PREDNISONE, THALIDOMIDE AND BORTEZOMIB IN ADVANCED AND REFRACTORY MULTIPLE MYELOMA PATIENTS.ADVANCED AND REFRACTORY MULTIPLE MYELOMA PATIENTS.MedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2004-000565-34-ITAZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
进行中（未招募）
不适用
A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE R-MPT IN ADVANCED, RELAPSED, REFRACTORY MULTIPLE MYELOMA PATIENTS. - R.MPTPatients with Multiple MyelomaMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2006-007087-28-ITFONDAZIONE NEOPLASIE SANGUE ONLUS
进行中（未招募）
1 期
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced CancerAdvanced Cancer Whose Tumours Contain Molecular AlterationsMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2020-002529-27-FRAstraZeneca AB52
进行中（未招募）
1 期
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced CancerAdvanced Cancer Whose Tumours Contain Molecular AlterationsMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104CTIS2024-515102-12-00AstraZeneca AB2
进行中（未招募）
不适用
A PHASE 1/2, MULTI-CENTER,OPEN LABEL STUDY OF THE SAFETY AND EFFICACY OF A STEPWISE DOSE-ESCALATION SCHEDULE OF LENALIDOMIDE MONOTHERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIAFor the treatment of relapsed or refractory B-CLL.MedDRA version: 8.1Level: LLTClassification code 10003946Term: B-Lymphocytic, CLL (Kiel Classification)EUCTR2006-004469-32-SECelgene Corporation124